Terumo Corporation’s (TRUMY) wholly-owned subsidiary MicroVention, Inc. recently announced the publication of the Clinical Evaluation of WEB 17 Device in Intracranial Aneurysms (CLEVER) study results.
The WEB™ Aneurysm Embolization System expands with a lower profile delivery system and new size configurations. ALISO VIEJO, Calif., Jan. 12, 2021 /PRNewswire/ -- MicroVention, Inc., a U.S.-based ...
ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, proudly marks the 15th anniversary of ...
For the new study, Dr. Adeeb and colleagues compared the WEB device in bifurcation and sidewall aneurysms using a large database spanning more than 10 years from the WorldWideWEB consortium, a group ...
Your donation today will help MinnPost continue to report on the news you need. Five years ago, Nancy Skoog-Edholm had no idea that she had two brain aneurysms. Then she started feeling sick. “I had a ...
SAN DIEGO & ALISO VIEJO, Calif.--(BUSINESS WIRE)--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, announced the publication of WEB-IT 5-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results